Leptin signaling and apoptotic effects in human prostate cancer cell lines

Prostate

Volumn 71, Issue 9, 2011, Pages 929-945

  Samuel Mendelsohn, Sigal ^a   Inbar, Michal ^a   Weiss Messer, Esther ^a   Niv Spector, Leonora ^b   Gertler, Arieh ^b   Barkey, Ronnie J ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

androgen receptor; apoptosis; kinase inhibitors; leptin mutein; leptin receptor antagonist; signaling pathways

Indexed keywords

CASPASE 3; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE 2; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMMUNOBLOTTING; KERATIN-18; LEPTIN; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION;

EID: 79955620715     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21309     Document Type: Article

References (61)

1. Knudsen KE, Penning TM,. Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21: 315-324.
2. Heemers HV, Tindall DJ,. Unraveling the complexities of androgen receptor signaling in prostate cancer cells. Cancer Cell 2009; 15: 245-247.
3. Nieto M, Finn S, Loda M, Hahn WC,. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 2007; 39: 1562-1568. (Pubitemid 47088307)
4. Ribeiro R, Lopes C, Medeiros R,. The link between obesity and prostate cancer: The leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 2006; 9: 19-24. (Pubitemid 43378863)
5. Buschemeyer WC III, Freedland SJ,. Obesity and prostate cancer: Epidemiology and clinical implications. Eur Urol 2007; 52: 331-343. (Pubitemid 46963472)
6. 2-terminal kinase. J Biol Chem 2003; 278: 42660-42667. (Pubitemid 37310540)
7. Hoda MR, Popken G,. Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int 2008; 102: 383-388. (Pubitemid 352019186)
8. Cirillo D, Rachiglio A, la Montagna R, Giordano A, Normanno N,. Leptin signaling in breast cancer: An overview. J Cell Biochem 2008; 105: 956-964.
9. Robertson SA, Leinninger GM, Myers J,. Molecular and neural mediators of leptin action. Physiol Behav 2008; 94: 637-642. (Pubitemid 351847627)
10. Fruhbeck G,. Intracellular signalling pathways activated by leptin. Biochem J 2006; 393: 7-20. (Pubitemid 43049298)
11. Eisenberg A, Biener E, Charlier M, Krishnan RV, Djiane J, Herman B, Gertler A,. Transactivation of erbB2 by short and long isoforms of leptin receptors. FEBS Lett 2004; 565: 139-142. (Pubitemid 38595334)
12. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H,. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 2008; 149: 9-14.
13. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, Molino A, Parolin V, Di Stefano B, Bonetti F, Giordano A, Cetto G, Surmacz E,. Leptin/HER2 crosstalk in breast cancer: In vitro study and preliminary in vivo analysis. BMC Cancer 2008; 8: 305.
14. Hynes NE, Lane HA,. ERBB receptors and cancer: The complexity of targeted inhibitors. Nature Rev Cancer 2005; 5: 341-354. (Pubitemid 40637826)
15. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M,. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006; 66: 5723-5728. (Pubitemid 43927125)
16. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, De Placido S,. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004; 90: 163-170. (Pubitemid 38745602)
17. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J,. Open-label phase ii study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 257-262. (Pubitemid 350003013)
18. Solit DB, Rosen N,. Targeting HER2 in prostate cancer: Where to next ? J Clin Oncol 2007; 25: 241-243. (Pubitemid 350003010)
19. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC,. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004; 188: 560-565. (Pubitemid 39491105)
20. Somasundar P, Yu AK, Vona-Davis L, McFadden DW,. Differential effects of leptin on cancer in vitro. J Surg Res 2003; 113: 50-55. (Pubitemid 36999792)
21. Mistry T, Digby JE, Desai KM, Randeva HS,. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int 2008; 101: 1317-1322. (Pubitemid 351549632)
22. Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, Raj MH, Rao PN,. Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells. J Biomed Biotechnol 2008; 2008: 163902.
23. Somasundar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, Jackson B, Vangilder R, Hileman SM, Vona-Davis LC,. Prostate cancer cell proliferation is influenced by leptin1. J Surg Res 2004; 118: 71-82. (Pubitemid 38490519)
24. Bidosee M, Karry R, Weiss-Messer E, Barkey RJ,. Growth hormone affects gene expression and proliferation in human prostate cancer cells. Int J Androl 2010 [Epub ahead of print], PMID: 20546049. DOI: 10.1111/j. 1365-2605.2010.0164. x.
25. Bidosee M, Karry R, Weiss-Messer E, Barkey RJ,. Regulation of growth hormone receptors in human prostate cancer cell lines. Mol Cell Endocrinol 2009; 309: 82-92.
26. Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ,. Growth hormone (GH) receptors in prostate cancer: Gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 2004; 220: 109-123. (Pubitemid 38757886)
27. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato ACB,. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999; 18: 6322-6329.
28. Niv-Spector L, Gonen-Berger D, Gourdou I, Biener E, Gussakovsky EE, Benomar Y, Ramanujan KV, Taouis M, Herman B, Callebaut I, Djiane J, Gertler A,. Identification of the hydrophobic strand in the A-B loop of leptin as major binding site III: Implications for large-scale preparation of potent recombinant human and ovine leptin antagonists. Biochem J 2005; 391: 221-230. (Pubitemid 41532418)
29. Kim GS, Hong JS, Kim SW, Koh JM, An CS, Choi JY, Cheng SL,. Leptin induces apoptosis via ERK/cPLA2/cytochrome c pathway in human bone marrow stromal cells. J Biol Chem 2003; 278: 21920-21929. (Pubitemid 36792599)
30. Ku NO, Liao J, Omary MB,. Apoptosis generates stable fragments of human type I keratins. J Biol Chem 1997; 272: 33197-33203. (Pubitemid 28023666)
31. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B,. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187: 567-572. (Pubitemid 29151999)
32. Schutte B, Henfling M, Kolgen W, Bouman M, Meex S, Leers MPG, Nap M, Bjorklund V, Bjorklund P, Bjorklund B, Lane EB, Omary MB, Jornvall H, Ramaekers FCS,. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004; 297: 11-26. (Pubitemid 38759558)
33. Gorina R, Sanfeliu C, Galito A, Messeguer N, Planas AM,. Exposure of glia to pro-oxidant agents revealed selective Stat1 activation by H202 and Jak2-independent antioxidant features of the Jak2 inhibitor AG490. Glia 2007; 55: 1313-1324. (Pubitemid 47328935)
34. Muniyappa H, Das KC,. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanism. Cell Signal 2008; 20: 675-683.
35. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG,. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278: 33753-33762. (Pubitemid 37553209)
36. Carson JP, Kulik G, Weber MJ,. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3â-kinase and Akt/protein kinase B. Cancer Res 1999; 59: 1449-1453. (Pubitemid 29160109)
37. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E,. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-540.
38. Koda M, Sulkowska M, Kanczuga-Koda L, Jarzabek KF, Sulkowski S,. Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folia Histochem Cytobiol 2007; 45 (Suppl 1): S187-S191.
39. Bowen C, Voeller HJ, Kikly K, Gelmann EP,. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death Differ 1999; 6: 394-401. (Pubitemid 29245953)
40. Bogazzi F, Russo D, Raggi F, Ultimieri F, Urbani C, Gasperi M, Bartalena L, Martino E,. Transgenic mice overexpressing growth hormone (GH) have reduced or increased cardiac apoptosis through activation of multiple GH-dependent or -independent cell death pathways. Endocrinology 2008; 149: 5758-5769.
41. Bruckheimer EM, Kyprianou N,. Dihydrotestosterone enhances transforming growth factor-ss-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 2001; 142: 2419-2426. (Pubitemid 32473098)
42. Duan WR, Gardner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EAG,. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003; 199: 221-228. (Pubitemid 36176028)
43. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S,. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006; 94: 1592-1598. (Pubitemid 43924919)
44. Linder S, Havelka AM, Ueno T, Shoshan MC,. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004; 214: 1-9. (Pubitemid 39141193)
45. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F,. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997; 27: 1-20. (Pubitemid 27059777)
46. Cohen B, Barkan D, Levy Y, Goldberg I, Fridman E, Kopolovic J, Rubinstein M,. Leptin induces angiopoietin-2 expression in adipose tissues. J Biol Chem 2001; 276: 7697-7700.
47. Qian H, Azain MJ, Compton MM, Hartzell DL, Hausman GJ, Baile CA,. Brain administration of leptin causes deletion of adipocytes by apoptosis. Endocrinology 1998; 139: 791-794. (Pubitemid 28513233)
48. Gullicksen PS, Della-Fera MA, Baile CA,. Leptin-induced adipose apoptosis: Implications for body weight regulation. Apoptosis 2003; 8: 327-335. (Pubitemid 36935204)
49. Sweeney G,. Leptin signalling. Cell Signal 2002; 14: 655-663. (Pubitemid 34518619)
50. 2-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochim Biophys Actaa-Mol Basis Dis 2008; 1782: 593-604.
51. Peters JH, Simasko SM, Ritter RC,. Leptin analog antagonizes leptin effects on food intake and body weight but mimics leptin-induced vagal afferent activation. Endocrinology 2007; 148: 2878-2885. (Pubitemid 46984789)
52. Elinav E, Niv-Spector L, Katz M, Price TO, Ali M, Yacobovitz M, Solomon G, Reicher S, Lynch JL, Halpern Z, Banks WA, Gertler A,. Pegylated leptin antagonist is a potent orexigenic agent: Preparation and mechanism of activity. Endocrinology 2009; 150: 3083-3091.
53. Gonzalez RR, Watters A, Xu Y, Singh U, Mann D, Rueda B, Penichet M,. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009; 11: R36.
54. Zhu ML, Kyprianou N,. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-849.
55. Comstock CE, Knudsen KE,. The complex role of AR signaling after cytotoxic insult: Implications for cell-cycle-based chemotherapeutics. Cell Cycle 2007; 6: 1307-1313. (Pubitemid 47327962)
56. Lin Y, Kokontis J, Tang F, Godfrey B, Liao S, Lin A, Chen Y, Xiang J,. Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol 2006; 26: 1908-1916.
57. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S,. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 2005; 65: 287-298. (Pubitemid 41759960)
58. Kim HJ, Park YI, Dong MS,. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays. Toxicol In Vitro 2006; 20: 1159-1167. (Pubitemid 44088595)
59. Rimler A, Lupowitz Z, Zisapel N,. Differential regulation by melatonin of cell growth and androgen receptor binding to the androgen response element in prostate cancer cells. Neuroendocrinol Lett 2002; 23 (Suppl 1): 45-49. (Pubitemid 34495381)
60. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM,. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000; 141: 1699-1704. (Pubitemid 32274399)
61. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H,. Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eur Urol 2001; 40: 241-251. (Pubitemid 34701893)